Guggenheim reiterates Buy on MBX Biosciences with $150 price target
Guggenheim maintained a Buy rating on MBX Biosciences's stock and set a price target of $150.00, implying a potential upside of 165.3% from the previous closing price.
Guggenheim maintained a Buy rating on MBX Biosciences's stock and set a price target of $150.00, implying a potential upside of 165.3% from the previous closing price.